<DOC>
	<DOCNO>NCT01647789</DOCNO>
	<brief_summary>This study ass safety preliminary antitumor activity CFG920 , new CYP17 inhibitor castration resistant prostate cancer patient abiraterone naive abiraterone resistant .</brief_summary>
	<brief_title>A Study Oral CFG920 Patients With Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Confirmed diagnosis castration resistant prostate cancer Documented metastases ECOG performance status 0 1 Documented progression follow Prostate Cancer Working Group 2 guideline Fresh archive tumor sample Impaired cardiac function Uncontrolled hypertension despire appropriate medical therapy History pituitary adrendal dysfunction Chronic steriod therapy daily use 10mg prednisone Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption oral CFG920 Brain metastases adequately treat Malignant disease treat study Laboratory abnormality specify protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>prostate cancer , castration resistant ,</keyword>
</DOC>